Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy

Authors: MK Schmidt, TC van Sprundel, MA Rookus, R Brohet, CJ van Asperen, EJTh Rutgers, RAEM Tollenaar, LJ van 't Veer

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Studies have shown that (bilateral) prophylactic mastectomy in genetically predisposed populations reduces the risk of breast cancer. Since BRCA1 and BRCA2 germline mutation testing became widely available (1995), breast cancer patients with a family history of breast cancer have also been tested. After having been identified as a BRCA1 or BRCA2 carrier, some women decide to undergo a contralateral prophylactic mastectomy (CPM) while others choose for intensive surveillance. The impact of this choice on contralateral breast cancer incidence and survival is still unknown. …
Metadata
Title
Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
Authors
MK Schmidt
TC van Sprundel
MA Rookus
R Brohet
CJ van Asperen
EJTh Rutgers
RAEM Tollenaar
LJ van 't Veer
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1096

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Oral Presentation

ATM mutations associated with breast cancer

Oral Presentation

Apoptotic chemotherapies

Oral Presentation

Biological features and xenograft models of a very early human premalignant breast lesion

Poster Presentation

The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells

Poster Presentation

Independent prognostic value of somatic TP53gene mutations in 1794 breast cancer patients

Oral Presentation

Proteomic approaches to early detection of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits